DOPTELET (avatrombopag) Now Available at Biologics by McKesson
Biologics selected for distribution network based on its expertise in high-touch support for oncology and complex disease patients CARY, N.C., […]
AYVAKIT™ (avapritinib), FDA Approved for Treatment of PDGFRA Exon 18 Mutant GIST, Available at Biologics by McKesson
CARY, N.C., Jan. 17, 2020—Biologics by McKesson, an independent specialty pharmacy for oncology and other rare and complex therapeutic areas, […]
TURALIO™ (pexidartinib), FDA Approved Treatment of TGCT, Available at Biologics by McKesson
Exclusive distribution agreement with Daiichi Sankyo, Inc. expands rare disease and complex therapeutic specialty pharmacy needs CARY, N.C. (August 7, […]
NUBEQA® (darolutamide), FDA Approved for Treatment of High-Risk Non-Metastatic Prostate Cancer, Available at Biologics by McKesson
CARY, N.C., August 1, 2019—Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, was selected […]
XPOVIO™ (selinexor) Available for Order at Biologics by McKesson
FDA-approved drug is new treatment option for patients with relapsed or penta-refractory multiple myeloma CARY, N.C., July 8, 2019—Biologics by […]
Biologics by McKesson Expands Specialty Pharmacy Capabilities to Serve Patients with Rare and Complex Conditions
Exclusive distribution agreement for rare disease therapy strengthens the specialty pharmacy’s footprint beyond oncology…
XOSPATA® (gilteritinib) Available at Biologics by McKesson
XOSPATA is FDA Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation…
COPIKTRA (duvelisib) Available for Order at Biologics by McKesson
COPIKTRA is a Dual Inhibitor Approved for Treatment of Adult Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma […]
TIBSOVO (ivosidenib), an IDH1 Inhibitor Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia with an IDH1 Mutation, Available for Order at Biologics by McKesson
CARY, N.C. (July 23, 2018) — Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, has […]
Combination Therapy BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the Treatment of BRAF-mutant Melanoma, Available for Order at Biologics by McKesson
CARY, N.C. (June 29, 2018) — Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, has […]